The epidemiology of Parkinson's disease: risk factors and prevention

A Ascherio, MA Schwarzschild - The Lancet Neurology, 2016 - thelancet.com
Since 2006, several longitudinal studies have assessed environmental or behavioural
factors that seem to modify the risk of developing Parkinson's disease. Increased risk of …

Neurotoxicity of methamphetamine: Main effects and mechanisms

S Jayanthi, AP Daiwile, JL Cadet - Experimental neurology, 2021 - Elsevier
Methamphetamine (METH) is an illicit psychostimulant that is abused throughout the world.
METH addiction is also a major public health concern and the abuse of large doses of the …

Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings

WJ Panenka, RM Procyshyn, T Lecomte… - Drug and alcohol …, 2013 - Elsevier
Methamphetamine (MA) is a highly addictive psychostimulant drug that principally affects the
monoamine neurotransmitter systems of the brain and results in feelings of alertness …

The main molecular mechanisms underlying methamphetamine-induced neurotoxicity and implications for pharmacological treatment

X Yang, Y Wang, Q Li, Y Zhong, L Chen… - Frontiers in molecular …, 2018 - frontiersin.org
Methamphetamine (METH) is a popular new-type psychostimulant drug with complicated
neurotoxicity. In spite of mounting evidence on METH-induced damage of neural cell, the …

Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms

R Moratalla, A Khairnar, N Simola, N Granado… - Progress in …, 2017 - Elsevier
Amphetamine-related drugs, such as 3, 4-methylenedioxymethamphetamine (MDMA) and
methamphetamine (METH), are popular recreational psychostimulants. Several preclinical …

[HTML][HTML] Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease

E Kip, LC Parr-Brownlie - Ageing Research Reviews, 2022 - Elsevier
Parkinson's disease (PD) is the second most common age-associated neurodegenerative
disorder and is characterised by progressive loss of dopamine neurons in the substantia …

New medications for drug addiction hiding in glutamatergic neuroplasticity

PW Kalivas, ND Volkow - Molecular psychiatry, 2011 - nature.com
The repeated use of drugs that directly or indirectly stimulate dopamine transmission carry
addiction liability and produce enduring pathological changes in the brain circuitry that …

Neurologic manifestations of chronic methamphetamine abuse

DE Rusyniak - Psychiatric Clinics, 2013 - psych.theclinics.com
Every decade seems to have its own unique drug problem. The 1970s had hallucinogens,
the 1980s had crack cocaine, the 1990s had designer drugs, the 2000s had …

Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology

S Yu, L Zhu, Q Shen, X Bai, X Di - Behavioural neurology, 2015 - Wiley Online Library
Methamphetamine (METH) is a sympathomimetic amine that belongs to phenethylamine
and amphetamine class of psychoactive drugs, which are widely abused for their stimulant …

Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs

RC Callaghan, JK Cunningham, J Sykes… - Drug and alcohol …, 2012 - Elsevier
BACKGROUND: Since methamphetamine and other amphetamine-type stimulants
(meth/amphetamine) can damage dopaminergic neurons, researchers have long …